EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer

Rui Han, Yimin Zhang, Tianhu Wang, Hualiang Xiao, Zhilin Luo, Cheng Shen, Jianghua Li, Chenglong Zhao, Li Li, Mengxiao Zhu, Haiwei Du iD, Huan Tang und 3 weitere

Cancer Science · 2023

DOI: 10.1111/cas.15778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Rui Han und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Graduate Scientific Research Innovation Project, Chongqing Science Technology Commission, Clinical Medical Research Talent Training Program of Army Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological response after neoadjuvant chemoimmunotherapy is significantly associated with survival outcomes. The aim of this retrospective study was to identify which population of patients with locally advanced and oligometastatic NSCLC has a favorable pathological response after neoadjuvant chemoimmunotherapy. NSCLC patients treated with neoadjuvant chemoimmunotherapy were enrolled between February 2018 and April 2022. Data on clinicopathological features were collected and evaluated. Multiplex immunofluorescence was performed on pre‐treatment puncture specimens and surgically resected specimens. In total, 29 patients with stages III and IV locally advanced or oligometastatic NSCLC who received neoadjuvant chemoimmunotherapy and R0 resection were enrolled. The results showed that 55% (16/29) of patients had a major pathological response (MPR) and 41% (12/29) of patients had a complete pathological response (pCR). In the stroma area of the pre‐treatment specimen, the higher infiltration of CD3 + PD‐L1 + tumor‐infiltrating lymphocytes (TILs) and the lower infiltration of CD4 + and CD4 + FOXP3 + TILs were more likely to appear in patients with pCR. However, in the tumor area, the higher infiltration of CD8 + TILs was more likely to appear in patients with non‐MPR. In the post‐treatment specimen, we found increased infiltration of CD3 + CD8 + , CD8 + GZMB + , and CD8 + CD69 + TILs and decreased infiltration of PD‐1 + TILs both in the stroma and tumor areas. Neoadjuvant chemoimmunotherapy achieved an MPR rate of 55% and induced greater immune infiltration. In addition, we observed that the baseline TILs and their spatial distribution correlate to the pathological response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNeoadjuvant TherapyRetrospective StudiesTumor MicroenvironmentLymphocytes, Tumor-InfiltratingB7-H1 Antigen

Stichwörter der Autor:innen

ATRPD-L1neoadjuvant chemoimmunotherapynon-small-cell lung cancerpathological responsetumor immune microenvironmenttumor mutation burden

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, China.
  • Burning Rock Biotech, Guangzhou, China.
  • Department of Thoracic Surgery, The Chongqing People's Hospital, Chongqing, China.

ORCID-Profile: Haiwei Du, Yong He

Förderung

  • Chongqing Graduate Scientific Research Innovation Project
  • Chongqing Science Technology Commission
  • Clinical Medical Research Talent Training Program of Army Medical University
  • Clinical Medical Technology Innovation Ability Training Program
  • Technology Project for Prevention and Control of Major Diseases in Chongqing
  • Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Han, R., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., Du, H., Tang, H., Ma, Z., Wang, Y., & He, Y. (2023). Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer. Cancer Science. https://doi.org/10.1111/cas.15778

Vancouver

Han R, Zhang Y, Wang T, Xiao H, Luo Z, Shen C, et al. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer. Cancer Science. 2023. doi:10.1111/cas.15778

BibTeX
@article{Han2023,
  author = {Han, Rui and Zhang, Yimin and Wang, Tianhu and Xiao, Hualiang and Luo, Zhilin and Shen, Cheng and Li, Jianghua and Zhao, Chenglong and Li, Li and Zhu, Mengxiao and Du, Haiwei and Tang, Huan and Ma, Zheng and Wang, Yubo and He, Yong},
  title = {Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer},
  journal = {Cancer Science},
  year = {2023},
  doi = {10.1111/cas.15778}
}
Kostenlos starten →